Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

neurological · Mechanism Report

Does neuroinflammation contribute to neurodegeneration in Alzheimer’s disease?

Neuroinflammation may contribute to amyloid-associated neurodegeneration, but direct causation in humans remains unproven.

PlausibleNovember 21, 20264 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Neural immune activation and neuroinflammation contribute causally to amyloid-associated neurodegeneration in Alzheimer's disease.

laying out figure…
0 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

Microglial activation and complement-linked synapse elimination provide plausible pathways connecting amyloid pathology to neuronal injury. Human imaging links immune activation with clinical worsening and brain-volume loss, but cannot establish whether it causes or follows injury.

Verified conclusion

Alzheimer’s disease involves amyloid accumulation, tau pathology, synaptic loss, and neurodegeneration; neural immune activation is increasingly implicated within this network. Current evidence supports neuroinflammation as a biologically credible contributor to amyloid-associated injury, but not as a definitively established upstream cause in humans.

Clinical and human imaging evidence

  • In amyloid-PET–positive patients followed longitudinally, increasing PBR28 TSPO-PET binding—a microglial-associated activation signal—tracked both worsening Clinical Dementia Rating–Sum of Boxes scores and cortical-volume loss.
  • These data link immune activation to clinically relevant progression and neurodegeneration, but do not demonstrate that the inflammatory signal preceded, rather than followed, neuronal injury. Associations with amyloid, tau, cognition, and atrophy remain compatible with pathogenic inflammation, a reactive response, or both.

Mechanistic evidence

  • Alzheimer risk is enriched in microglial and immune-pathway genetics. In particular, TREM2 loss-of-function variants materially increase disease risk, while experimental findings indicate that TREM2-dependent microglial responses can compact plaques and limit neuritic damage.
  • Complement signaling through C1q/C3/CR3 provides a coherent mechanism for immune-mediated synapse elimination. Perturbation studies support complement-linked pruning, and complement and synaptic abnormalities are observed in Alzheimer tissue. This may connect amyloid pathology to synaptic loss, although human tissue findings cannot establish temporal initiation.
  • Immune activation is not uniformly harmful: microglial responses may also promote plaque containment, clearance, and repair depending on disease stage and context.

Therapeutic implications

  • The TREM2 agonist AL002 achieved CNS target engagement in INVOKE-2 but did not improve clinical progression versus placebo. NLRP3- and complement-directed strategies remain principally preclinical, with variable results.

Bottom line

  • Neuroinflammation plausibly contributes causally to amyloid-associated neurodegeneration through microglial and complement-linked pathways, but direct human temporal causation and disease-modifying clinical benefit from immune-targeted treatment remain unproven.

References

  1. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease — pmc.ncbi.nlm.nih.gov ↗
  2. Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease | Neurology Neuroimmunology & Neuroinflammation — neurology.org ↗
  3. Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model — onlinelibrary.wiley.com ↗
  4. Microglia-mediated neuroinflammation in Alzheimer’s disease ... — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible9 sourcesCan environmental chemicals contribute to neuroimmune inflammation and neural injury?→Plausible7 sourcesCan anti-Ri antibodies signal cancer-related neurologic autoimmunity after breast cancer?→